CTTI to Host 10/5 Webinar on “Next Steps for Obtaining Novel Endpoint Reliability & Acceptance”
On Oct. 5 at noon ET, the Clinical Trials Transformation Initiative (CTTI) will host a public webinar on “Next Steps for Obtaining Novel Endpoint Reliability & Acceptance” – the third in a series of webinars on using novel digitally derived endpoints in clinical trials for medical product development from CTTI, Digital Medicine Society (DiMe), and TransCelerate.
Presenters Lindsay Kehoe, CTTI, and Alicia Staley, Medidata, will discuss CTTI’s current work to obtain reliability and acceptance of meaningful, digitally derived novel endpoints – a project that builds on its existing novel endpoint development recommendations and resources from 2017.
Attendees will hear:
- Highlights from a recent Expert Meeting of leaders and stakeholders from across the clinical trials ecosystem
- Insights from in-depth interviews with sponsors
- A preview of the forthcoming set of CTTI novel endpoint recommendations and resources.
This webinar builds on recent webinars by DiMe, which focused on the best resources currently available for using digitally derived endpoints, and TransCelerate, which demonstrate key considerations and challenges for developing novel digital endpoints through a hypothetical case study.
“As the novel endpoints space continues to evolve, CTTI, DiMe and TransCelerate are committed to working together to help stakeholders across the clinical trials enterprise evolve with it,” said Kehoe. “By encouraging greater collaboration and innovation among technology companies, academic investigators, patients, regulators and trial sponsors and sites, we can accelerate progress to the benefit of everyone involved.”
Register to attend “Next Steps for Obtaining Novel Endpoint Reliability & Acceptance” today.